If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
572.00    33.00 (6.12%)
Bid:
569.00
Ask:
570.00
Spread: 1.00 (0.176%)
Market Cap: £1.55b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

Directorate Change

24 Jun 2014 07:00

RNS Number : 3280K
Chemring Group PLC
24 June 2014
 



 FOR IMMEDIATE RELEASE 24 JUNE 2014

 

CHEMRING GROUP PLC

 

Directorate change

 

Michael Flowers appointed Group Chief Executive

 

Chemring Group PLC ("Chemring" or "the Group") announces that Michael Flowers has been appointed Group Chief Executive with immediate effect. Michael joined Chemring in 2006 and prior to today's appointment was Group Director, Countermeasures and a member of Chemring's Executive Committee.

 

Michael Flowers has spent 13 years in senior management positions within the defence industry. He previously served as an officer in the Australian Army for 22 years and was a graduate of the Australian Command and Staff College and the British Royal Military College of Science. After leaving the army, he was a senior manager at BAE Systems from 2001 to 2006, in programme and project management roles.

 

From 2006, he was Managing Director, Chemring Australia, where he established a state of the art countermeasures manufacturing facility and delivered substantial growth in the defence portfolio. In 2013, he was appointed Group Director, Munitions, with responsibility for Chemring's European munitions business. Michael led the successful sale of the European munitions business following the 2013 strategic review, working closely with Chemring's Board and advisers to negotiate and complete the disposal in May 2014.

 

Mark Papworth has stepped down from the Board of Chemring with immediate effect. 

 

Peter Hickson, Chairman of Chemring, said:

 

"Michael Flowers has a proven track record, both within the international defence industry and within Chemring, where he led our Australian business through a successful period of growth and, more recently, managed the complex disposal process of the European munitions business. Michael is extremely knowledgeable about our markets and is well qualified to lead Chemring as we capitalise on our world leading technologies in Countermeasures, Sensors & Electronics and Energetic Systems.

 

Much has been achieved during Mark Papworth's tenure, including a significant reorganisation and refocusing of the Group and a substantial reduction in the cost base and we are grateful for his leadership during this period.

 

We are now moving from a period of critical and significant change to one where we must take maximum advantage of the stronger platform that has been created. To achieve this, a different set of skills is required in the role of Chief Executive, in particular extensive knowledge and understanding of the defence markets in which we operate."

 

Michael Flowers has a beneficial shareholding of 80,680 Chemring shares.

 

There is no further information to be disclosed pursuant to paragraph 9.6.13R of the UK Listing Rules in relation to Michael Flowers' appointment as a director of Chemring.

 

Ends

 

 

 

 

For further information, contact:

 

Chemring Group PLC 01489 881 880

Peter Hickson, Chairman

Steve Bowers, Finance Director

Rupert Pittman, Group Director of Communications and Investor Relations

 

MHP Communications 020 3128 8100

Andrew Jaques

John Olsen

James White

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOADDGDLSBDBGSX
Date   Source Headline
13th Feb 20177:00 amRNSCONTRACT AWARD
1st Feb 201710:56 amRNSTotal Voting Rights
30th Jan 201711:13 amRNSDirector/PDMR Shareholding
24th Jan 20179:27 amRNSDirector/PDMR Shareholding
20th Jan 201711:08 amRNSDirector/PDMR Shareholding
20th Jan 201711:05 amRNSDirector/PDMR Shareholding
19th Jan 20172:13 pmRNSDirector/PDMR Shareholding
19th Jan 20177:00 amRNSFinal Results
3rd Jan 201710:00 amRNSTotal Voting Rights
13th Dec 20167:00 amRNSDirectorate Change
1st Dec 20169:34 amRNSTotal Voting Rights
21st Nov 20167:00 amRNSPOST-CLOSE STATEMENT
1st Nov 20169:40 amRNSTotal Voting Rights
3rd Oct 201610:10 amRNSTotal Voting Rights
29th Sep 201610:53 amRNSContract Win
1st Sep 20169:05 amRNSTotal Voting Rights
31st Aug 20167:00 amRNSQ3 UPDATE
25th Aug 20163:32 pmRNSHolding(s) in Company
17th Aug 201611:31 amRNSHolding(s) in Company
12th Aug 20169:34 amRNSDirector/PDMR Shareholding
3rd Aug 20169:43 amRNSTotal Voting Rights
28th Jul 201612:29 pmRNSDirector/PDMR Shareholding
22nd Jul 201610:07 amRNSHolding(s) in Company
21st Jul 20167:00 amRNSContract Win
18th Jul 20163:41 pmRNSHolding(s) in Company
4th Jul 20162:22 pmRNSHolding(s) in Company
1st Jul 20169:50 amRNSTotal Voting Rights
29th Jun 20167:00 amRNSDirectorate Change
28th Jun 20169:20 amRNSHolding(s) in Company
23rd Jun 201611:21 amRNSHolding(s) in Company
22nd Jun 20169:15 amRNSDirector/PDMR Shareholding
21st Jun 20161:12 pmRNSDirector/PDMR Shareholding
21st Jun 20167:00 amRNSINTERIM RESULTS
20th Jun 20162:39 pmRNSBlock listing Interim Review
20th Jun 20162:37 pmRNSBlock listing Interim Review
1st Jun 201611:01 amRNSTotal Voting Rights
17th May 20167:00 amRNSDirectorate Change
10th May 20164:20 pmRNSDirector/PDMR Shareholding
5th May 20167:00 amRNSCompletion of Acquisition
3rd May 201610:08 amRNSTotal Voting Rights
27th Apr 20162:13 pmRNSDirectorate Change
25th Apr 20169:52 amRNSDirector/PDMR Shareholding
19th Apr 20167:00 amRNSAPPOINTMENT OF CHAIRMAN-DESIGNATE
6th Apr 20164:15 pmRNSDirector/PDMR Shareholding
4th Apr 20167:00 amRNSContract Update
1st Apr 20169:48 amRNSTotal Voting Rights
24th Mar 201610:36 amRNSHolding(s) in Company
21st Mar 20162:05 pmRNSResult of AGM
21st Mar 201611:00 amRNSAGM Trading Update
8th Mar 20162:36 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.